Kidney Transplant Failure and Rejection Clinical Trial
Official title:
ASSOCIATION OF miRNA WITH ALLOGRAFT FUNCTION AND EXPRESSION PROFILES PREDICTIVE OF DISEASES OCCURING AFTER KIDNEY TRANSPLANTATION
NCT number | NCT04413916 |
Other study ID # | P20190104 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2019 |
Est. completion date | December 31, 2019 |
Verified date | May 2020 |
Source | University Medical Centre Ljubljana |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
MicroRNAs (miRNAs) belong to a class of small non-coding RNAs that modulate physiological and
pathological processes by post-transcriptional regulation of gene expression mainly via
translational inhibition of target messenger RNAs. Recently, many miRNAs were found to be
involved in pathological processes that occur following kidney transplantation, like
allograft rejection, de novo disease or disease recurrence after kidney transplantation. As
most of the miRNAs involved in kidney diseases are extracted by urine, the diagnostic
accuracy of such molecules as biomarkers is questionable.
The aim of this study is to analyze expression of selected miRNAs (miR-29c, miR-126,
miR-146a, miR-150, miR-155, miR-223) and evaluate whether their regulation is associated with
kidney graft function and disease processes after kidney transplantation (KTx).
Status | Completed |
Enrollment | 100 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - time of kidney transplantation at least 2 years before the study entry, - stable function of the transplanted kidney during the previous 3 months (changes in s-creatinine = 20%). Exclusion criteria: - age less than 18 years, - symptomatic heart failure, - malignancy, - pregnancy or lactation, - acute conditions and diseases that can affect the GFR, - newly-introduced drugs that may affect the function of the graft, - treatment with trimethoprim-sulfamethoxazole or cimetidine, - the presence of a pacemaker or any other electronic device in the body. |
Country | Name | City | State |
---|---|---|---|
Slovenia | University Medical Centre Ljubljana | Ljubljana |
Lead Sponsor | Collaborator |
---|---|
University Medical Centre Ljubljana |
Slovenia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Association of miRNA and kidney graft function | correlation of selected miRNAs expression with parameters of kidney graft function | sample collection within one month of enrollement | |
Secondary | Association of miRNAs expression and kidney graft rejection or disease recurrence | Correlation of selected miRNAs expression and kidney graft rejection or disease recurrence | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04057742 -
AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
|
||
Recruiting |
NCT03465397 -
Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients
|
Phase 4 | |
Completed |
NCT03437577 -
Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05282966 -
Assessment of QSantâ„¢ for Underlying Allograft Rejection
|
||
Recruiting |
NCT04388930 -
The Microbiota in Kidney Donation and Transplantation
|
||
Completed |
NCT03611621 -
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
|
||
Recruiting |
NCT05397821 -
Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
|
||
Completed |
NCT04019353 -
Cf-DNA Assay During Treatment of Acute Rejection
|
||
Active, not recruiting |
NCT05806749 -
Immunological Tolerance in Patients With Mismatched Kidney Transplants
|
Phase 1 | |
Recruiting |
NCT04936282 -
Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)
|
Phase 4 | |
Enrolling by invitation |
NCT05285878 -
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
|
Phase 2 | |
Recruiting |
NCT04526431 -
Tacrolimus Pharmacokinetic Subpopulations
|
||
Active, not recruiting |
NCT03511560 -
Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
|
Phase 4 | |
Recruiting |
NCT03438773 -
Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients
|
Phase 1 | |
Completed |
NCT05388955 -
Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
|
||
Completed |
NCT06394596 -
Predicting Prognostic Factors in Kidney Transplantation Using A Machine Learning
|
||
Completed |
NCT03466775 -
Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes
|
N/A | |
Active, not recruiting |
NCT04733131 -
Long-term Outcomes After Conversion to Belatacept
|
||
Active, not recruiting |
NCT03380962 -
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04154267 -
Protocol Biopsies in High-risk Renal Transplant Recipients
|
N/A |